



IMDRF
International Medical Device
Regulators Forum

EU2023
EUROPEAN UNION
Chair

13:45 – 14:00

Personalized Medical Devices (Australia)



Tracey Duffy

First Assistant Secretary, Medical Devices and Product
Quality Division, Therapeutic Goods Administration (TGA)





Personalized Medical Devices (PMD) Working Group

PMD Working Group Chair: Therapeutic Goods Administration, Australia


Tasks given to the PMD Working Group

1. Revise PMD Regulatory Pathways (N58)

[Public consultation closed 28 November 2022](#)

2. Develop PMD Production Verification and Validation (N74)

[Public consultation closed 28 December 2022](#)



PMD Regulatory Pathways (N58)


[N58](#), first published in 2020, is an active technical document.

In April 2022, MC approved the proposal to revise N58 to achieve the following objectives:


1. Revise the **definition** of Medical Device Production System (MDPS) to no longer limit the concept to PMDs;
2. Revise the MDPS framework to better represent **real world applications**, thereby facilitating the adoption and implementation of MDPSs by stakeholders; and
3. Expand the scope of Appendix 2 to incorporate a broad range of medical devices, **not limited to PMDs**.



Timelines & progress on the revision of N58



Timelines & progress on the revision of N58



Public consultation – N58 PMD Regulatory Pathways

Start date: Thursday, 29 September 2022 | Closing date: Monday, 28 November 2022

- Eleven submissions received – 61 comments
- Submissions received from individuals, peak bodies representing allied health and dental sectors, and trade associations representing industry
- The WG held deep dive sessions in February 2023 to consider the feedback received in the submissions
- An updated version of the document has been submitted to the MC for consideration



Observations from N58 public consultation


- Stakeholders broadly supported the revisions; requested further clarification on delineation of roles and responsibilities of HCF and MDPS manufacturers
- Some feedback was not within the scope of revisions:
 - changing the PMD definitions
 - seeking to have IVD medical devices included in the scope
- Stakeholders sought further clarification on how PMDs will be regulated in their jurisdiction




PMD Production Verification and Validation (N74)

New Work Item Extension (NWIE) approved by MC in September 2020 to develop technical guidance covering:

- Part I: Verification and validation aspects of **Specified Design Envelope** (salient feature of patient-matched medical device definition)
- Part II: Verification and validation **aspects** of MDPS



Timelines & progress on the development of N74




Timelines & progress on the development of N74



Public consultation – N74 PMD Production V&V

Start date: Thursday, 29 September 2022 | Closing date: Wednesday, 28 December 2022

- Four submissions received – 49 comments
- The WG held deep dive sessions in February 2023 to consider the feedback received in the submissions
- An updated version of the document has been submitted to the MC for consideration



Observations from N74 public consultation

- Limited feedback on N74, likely because the concepts presented are relatively novel and stakeholders do not have enough experience yet
- Specific feedback and broad agreement on Specified Design Envelope V&V recommendations
- Further clarification sought on the delineation of roles and responsibilities of the HCF and MDPS manufacturers at various stages of its life-cycle



Summary

- WG has met virtually 17 times since December 2020, most recently on Thursday, 2 March 2023
- WG held five deep dive sessions in February 2023 to discuss the feedback from public consultation on N58 and N74
- Outcomes from deep dive sessions in February 2023 - updated versions of N58 and N74 (Proposed Documents)
- N58 and N74 Proposed Documents have been submitted to the IMDRF Secretariat for consideration by MC at March 2023 meeting



Personalised Medical Devices Working Group (WG) members

Jurisdictions

Argentina
Australia
Brazil
Canada
China
Europe
Japan
Saudi Arabia
Singapore
South Korea
UK
USA



Thank you/Questions

PMD Working Group Chair: Therapeutic Goods Administration, Australia
Email: personaliseddevices@health.gov.au

Disclaimer

This document was produced by the International Medical Device Regulators Forum. There are no restrictions on the reproduction or use of this document; however, incorporation of this document, in part or in whole, into another document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.

Copyright 2021 by the International Medical Device Regulators Forum.